Krebs Biochemicals & Industries Limited (KREBSBIO) Financial History

Name: Krebs Biochemicals & Industries Limited (KREBSBIO) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Krebs Biochemicals & Industries Limited (KREBSBIO) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Visakhapatnam, India with about 142 employees. Its market capitalization is roughly ₹1 billion. In the fiscal year ended 2026-03-31, KREBSBIO reported ₹237M in revenue and (₹169M) in net income.

Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry.

Interactive charts & full statements →

KREBSBIO Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹237M	₹433M	₹504M	₹521M	—
Gross Profit	₹134M	₹164M	₹193M	₹98M	—
Operating Income (EBIT)	(₹79M)	(₹213M)	(₹152M)	(₹219M)	—
Net Income	(₹169M)	(₹269M)	(₹197M)	(₹247M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KREBSBIO Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹70M	₹68M	₹73M	₹42M	₹55M
Gross Profit	₹66M	₹67M	₹73M	₹42M	₹52M
Operating Income (EBIT)	(₹8M)	(₹24M)	(₹13M)	(₹44M)	(₹37M)
Net Income	(₹25M)	(₹23M)	(₹31M)	(₹61M)	(₹53M)

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KREBSBIO Free Cash Flow History

KREBSBIO Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹1.6B	₹1.7B	₹1.8B	₹1.7B	—
Total Liabilities	₹3.3B	₹3.2B	₹3.0B	₹2.7B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KREBSBIO viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

2161 · JBM (Healthcare) Limited — HK$1 billion
BALAXI · Balaxi Pharmaceuticals Limited — ₹1 billion
1061 · Essex Bio-Technology Limited — HK$1 billion
ALPA · Alpa Laboratories Limited — ₹1 billion
VAISHALI · Vaishali Pharma Limited — ₹1 billion
MAKERSL · Makers Laboratories Limited — ₹1 billion
GUD · Knight Therapeutics Inc. — C$1 billion
ESPR · Esperion Therapeutics, Inc. Common Stock — $819 million

← KRE All “K” companies KREF →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.